Peptide And Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)
The Peptide And Oligonucleotide CDMO Market size is estimated at USD 2.40 billion in 2024, and is expected to reach USD 4.67 billion by 2029, growing at a CAGR of 11.70% during the forecast period (2024-2029).
The market increases due to the rising demand for peptide and oligonucleotide-based therapeutics, advancements in peptide synthesis and oligonucleotide manufacturing technologies, and the growing outsourcing trend in the pharmaceutical industry. Peptides and oligonucleotides offer a more targeted and personalized approach to treating diseases. They are designed to interact with specific molecular targets, providing precision in therapeutic interventions. These molecules are being explored for various therapeutic areas, including cancer, genetic disorders, and metabolic diseases. Oligonucleotides, for instance, are gaining attention for their potential in addressing genetic mutations. CDMOs often specialize in synthesizing and manufacturing specific types of molecules, including peptides and oligonucleotides. Their expertise ensures efficient and high-quality production, ensuring the therapeutic molecules meet the required standards.
Collaboration and partnerships within the pharmaceutical industry can significantly boost the peptide and oligonucleotide CDMO market. For instance, in May 2023, PolyPeptide and Numaferm signed a Preferred Partner Collaboration Agreement for peptide development and production, leveraging PolyPeptide’s cGMP manufacturing capacities, regulatory know-how, and market access and Numaferm’s biochemical production platform and expertise in sustainable peptide manufacturing.
Similarly, in August 2023, EUROAPI and the shareholders of BianoGMP, a CDMO, signed a share purchase and transfer agreement under which EUROAPI will acquire 100% of Biano shares. The deal enhances EUROAPI’s attractiveness for early-phase (preclinical and Phase 1) oligonucleotide projects.
Hence, increasing demand for peptide and oligonucleotide-based therapeutics and strategic partnerships is expected to contribute to the market growth during the forecast period. However, stringent regulatory policies and the high cost associated with the therapy are expected to restrain the market during the forecast period.
Peptide And Oligonucleotide CDMO Market Trends
The Therapeutics Segment Holds a Significant Market Share and is Expected to Continue the Same During the Forecast Period
Peptide and oligonucleotide therapeutics possess multifaceted applications and share manufacturing and regulatory similarities, with advancements in formulation increasing product complexity and necessitating innovative solutions. Collaboration with a proficient contract development and manufacturing organization facilitates drug developers' manufacturing requirements, enabling them to prioritize their development efforts.
The therapeutic application of peptides and oligonucleotides is expected to increase drug development activities and contribute to market growth. Peptides are being explored for targeted cancer therapies and managing conditions like diabetes. The growing burden of these diseases is expected to propel the segment's growth. For instance, according to 2024 statistics published by the American Cancer Society (ACS), the incidence of cancer cases was estimated to increase from 1.93 million in 2021 to 2.00 million in 2023, a rise of more than 60 thousand cases in two years, demonstrating a rapid growth in the incidence of cancer cases in the country. Peptides and oligonucleotides are being explored for targeted cancer therapies. CDMOs contribute to the development and production of peptide-based anticancer drugs.
Moreover, the launch of peptides and oligonucleotides production capacity is expected to boost the market during the forecast period. For instance, in September 2023, CordenPharma announced the inauguration of increased commercial peptide production capacity with newly upgraded facilities at CordenPharma Colorado, the largest solid-phase peptide synthesis (SPPS) manufacturing facility worldwide.
Hence, the therapeutic applications of peptides and oligonucleotides, along with the strategic initiatives taken by market players, are expected to drive the growth of this segment during the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
In North America, the peptide and oligonucleotide CDMO market is expected to grow owing to established research facilities, high investment in R&D for peptide and oligonucleotide-based therapeutics, and the growing burden of chronic diseases. The demand for biopharmaceuticals, including peptides and oligonucleotides, has been rising. CDMOs in North America are well-positioned to cater to this demand by offering specialized services in developing and manufacturing these complex molecules.
Continuous investments in research and development activities by pharmaceutical and biotech companies contribute to expanding the peptides and oligonucleotide CDMO market. These investments often involve collaborations with CDMOs to access specialized expertise and infrastructure. For instance, in January 2023, Agilent Technologies Inc. invested approximately USD 725 million to double the manufacturing capacity of therapeutic nucleic acids in response to the market's rapid growth. This investment reflects the strong demand for therapeutic oligonucleotide and the unmatched quality and service of therapeutic oligonucleotide contract development and manufacturing organization.
Additionally, in December 2022, Asymchem Laboratories (Tianjin) Co. Ltd, a CDMO, announced the opening of a new site in Woburn, Massachusetts. The latest Boston site provides early-stage R&D services, including small molecules, peptides, and oligonucleotides.
Hence, the North American peptides and oligonucleotide CDMO market is expected to boost due to increasing demand, advancements in therapeutics, outsourcing trends, regulatory support, and R&D investments.
Peptide And Oligonucleotide CDMO Industry Overview
The market for peptide and oligonucleotide contract development and manufacturing organizations is moderately competitive, with both small and large players involved in strategic activities such as the expansion of services, partnerships, collaborations, as well as mergers, and acquisitions. Key players are Thermo Fisher Scientific Inc., Polypeptide Group, Wuxi Apptec Co. Ltd, Genscript Biotech Corporation, and CordenPharma International.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
The market increases due to the rising demand for peptide and oligonucleotide-based therapeutics, advancements in peptide synthesis and oligonucleotide manufacturing technologies, and the growing outsourcing trend in the pharmaceutical industry. Peptides and oligonucleotides offer a more targeted and personalized approach to treating diseases. They are designed to interact with specific molecular targets, providing precision in therapeutic interventions. These molecules are being explored for various therapeutic areas, including cancer, genetic disorders, and metabolic diseases. Oligonucleotides, for instance, are gaining attention for their potential in addressing genetic mutations. CDMOs often specialize in synthesizing and manufacturing specific types of molecules, including peptides and oligonucleotides. Their expertise ensures efficient and high-quality production, ensuring the therapeutic molecules meet the required standards.
Collaboration and partnerships within the pharmaceutical industry can significantly boost the peptide and oligonucleotide CDMO market. For instance, in May 2023, PolyPeptide and Numaferm signed a Preferred Partner Collaboration Agreement for peptide development and production, leveraging PolyPeptide’s cGMP manufacturing capacities, regulatory know-how, and market access and Numaferm’s biochemical production platform and expertise in sustainable peptide manufacturing.
Similarly, in August 2023, EUROAPI and the shareholders of BianoGMP, a CDMO, signed a share purchase and transfer agreement under which EUROAPI will acquire 100% of Biano shares. The deal enhances EUROAPI’s attractiveness for early-phase (preclinical and Phase 1) oligonucleotide projects.
Hence, increasing demand for peptide and oligonucleotide-based therapeutics and strategic partnerships is expected to contribute to the market growth during the forecast period. However, stringent regulatory policies and the high cost associated with the therapy are expected to restrain the market during the forecast period.
Peptide And Oligonucleotide CDMO Market Trends
The Therapeutics Segment Holds a Significant Market Share and is Expected to Continue the Same During the Forecast Period
Peptide and oligonucleotide therapeutics possess multifaceted applications and share manufacturing and regulatory similarities, with advancements in formulation increasing product complexity and necessitating innovative solutions. Collaboration with a proficient contract development and manufacturing organization facilitates drug developers' manufacturing requirements, enabling them to prioritize their development efforts.
The therapeutic application of peptides and oligonucleotides is expected to increase drug development activities and contribute to market growth. Peptides are being explored for targeted cancer therapies and managing conditions like diabetes. The growing burden of these diseases is expected to propel the segment's growth. For instance, according to 2024 statistics published by the American Cancer Society (ACS), the incidence of cancer cases was estimated to increase from 1.93 million in 2021 to 2.00 million in 2023, a rise of more than 60 thousand cases in two years, demonstrating a rapid growth in the incidence of cancer cases in the country. Peptides and oligonucleotides are being explored for targeted cancer therapies. CDMOs contribute to the development and production of peptide-based anticancer drugs.
Moreover, the launch of peptides and oligonucleotides production capacity is expected to boost the market during the forecast period. For instance, in September 2023, CordenPharma announced the inauguration of increased commercial peptide production capacity with newly upgraded facilities at CordenPharma Colorado, the largest solid-phase peptide synthesis (SPPS) manufacturing facility worldwide.
Hence, the therapeutic applications of peptides and oligonucleotides, along with the strategic initiatives taken by market players, are expected to drive the growth of this segment during the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
In North America, the peptide and oligonucleotide CDMO market is expected to grow owing to established research facilities, high investment in R&D for peptide and oligonucleotide-based therapeutics, and the growing burden of chronic diseases. The demand for biopharmaceuticals, including peptides and oligonucleotides, has been rising. CDMOs in North America are well-positioned to cater to this demand by offering specialized services in developing and manufacturing these complex molecules.
Continuous investments in research and development activities by pharmaceutical and biotech companies contribute to expanding the peptides and oligonucleotide CDMO market. These investments often involve collaborations with CDMOs to access specialized expertise and infrastructure. For instance, in January 2023, Agilent Technologies Inc. invested approximately USD 725 million to double the manufacturing capacity of therapeutic nucleic acids in response to the market's rapid growth. This investment reflects the strong demand for therapeutic oligonucleotide and the unmatched quality and service of therapeutic oligonucleotide contract development and manufacturing organization.
Additionally, in December 2022, Asymchem Laboratories (Tianjin) Co. Ltd, a CDMO, announced the opening of a new site in Woburn, Massachusetts. The latest Boston site provides early-stage R&D services, including small molecules, peptides, and oligonucleotides.
Hence, the North American peptides and oligonucleotide CDMO market is expected to boost due to increasing demand, advancements in therapeutics, outsourcing trends, regulatory support, and R&D investments.
Peptide And Oligonucleotide CDMO Industry Overview
The market for peptide and oligonucleotide contract development and manufacturing organizations is moderately competitive, with both small and large players involved in strategic activities such as the expansion of services, partnerships, collaborations, as well as mergers, and acquisitions. Key players are Thermo Fisher Scientific Inc., Polypeptide Group, Wuxi Apptec Co. Ltd, Genscript Biotech Corporation, and CordenPharma International.
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definitions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand For Peptide And Oligonucleotide-Based Therapeutics
4.2.2 Advancements In Peptide Synthesis And Oligonucleotide Manufacturing Technologies
4.2.3 Increasing Outsourcing Trend In The Pharmaceutical Industry
4.3 Market Restraints
4.3.1 Regulatory Challenges
4.3.2 Manufacturing Capacity Constraints and Intellectual Property Concerns
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE – USD)
5.1 By Product
5.1.1 Peptide CDMO
5.1.2 Oligonucleotide CDMO
5.2 By Application
5.2.1 Therapeutics
5.2.2 Research Applications
5.2.3 Diagnostics
5.2.4 Other Application
5.3 End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Research Organization
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 United Kingdom
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Spain
5.4.2.5 Italy
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 India
5.4.3.2 Japan
5.4.3.3 China
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of the Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc.
6.1.2 Merck KGaA
6.1.3 Catalent, Inc.
6.1.4 Genscript Biotech Corporation
6.1.5 Polypeptide Group
6.1.6 Bachem Holding AG
6.1.7 Ajinomoto Co. Inc.
6.1.8 Wuxi Apptec Co. Ltd
6.1.9 Rentschler Biopharma SE
6.1.10 CordenPharma International
6.1.11 Senn Chemicals AG
6.1.12 PolyPeptide Group
6.1.13 Almac Group
6.1.14 Lonza
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
1.1 Study Assumptions and Market Definitions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand For Peptide And Oligonucleotide-Based Therapeutics
4.2.2 Advancements In Peptide Synthesis And Oligonucleotide Manufacturing Technologies
4.2.3 Increasing Outsourcing Trend In The Pharmaceutical Industry
4.3 Market Restraints
4.3.1 Regulatory Challenges
4.3.2 Manufacturing Capacity Constraints and Intellectual Property Concerns
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (MARKET SIZE BY VALUE – USD)
5.1 By Product
5.1.1 Peptide CDMO
5.1.2 Oligonucleotide CDMO
5.2 By Application
5.2.1 Therapeutics
5.2.2 Research Applications
5.2.3 Diagnostics
5.2.4 Other Application
5.3 End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Research Organization
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 United Kingdom
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Spain
5.4.2.5 Italy
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 India
5.4.3.2 Japan
5.4.3.3 China
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of the Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc.
6.1.2 Merck KGaA
6.1.3 Catalent, Inc.
6.1.4 Genscript Biotech Corporation
6.1.5 Polypeptide Group
6.1.6 Bachem Holding AG
6.1.7 Ajinomoto Co. Inc.
6.1.8 Wuxi Apptec Co. Ltd
6.1.9 Rentschler Biopharma SE
6.1.10 CordenPharma International
6.1.11 Senn Chemicals AG
6.1.12 PolyPeptide Group
6.1.13 Almac Group
6.1.14 Lonza
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
